Speak with an adviser 916.900.2998

Start Here
Media

Paul Seegert weighs in on COVID-19 Vaccine Distribution and Planning

Pharmaceutical giant Pfizer and biotech firm Moderna has recently announced the results of their clinical trials for their vaccines against COVID-19.

In a test conducted by Pfizer on 43,538 people in six countries, final data suggests a 95% efficacy. On the other hand, Moderna confirms that their vaccine is almost 95% effective after conducting a trial of over 30,000 people. Meanwhile, another vaccine is being developed by Oxford University and biotech firm AstraZeneca that is now on average 70.4% effective.

Both Pfizer and Moderna are set to apply for emergency authorization from the Food and Drug Administration. Once approved, both companies are set to produce millions of doses to be distributed by next year.

The three mentioned companies only represent a fraction of various clinical trials that are being done right now.

With all these ongoing clinical trials and the nearing possibility of having a vaccine that will put an end to the pandemic, the next question is, how do we handle the planning and distribution of these vaccines? Find out through this interview of PCS Adviser’s Managing Partner Paul Seegert with Scott Sloan of 700 WLW Radio, Cincinatti.

Listen to the full interview here:


Recent Interviews Related to this Topic:

Paul Seegert and Scott Sloan of 700 WLW Radio talks about the UK’s recent emergency approval of Pfizer and BioNTech COVID-19 vaccine and why US hasn’t done it yet. (03 December 2020)


With the UK’s recent approval of Pfizer and BioNTech led COVID-19 vaccines, why is it that the US seems to be lagging behind? Jeff Angelo of WHO Radio taps PCS Adviser’s Managing Partner Paul Seegert to answer this question. (03 December 2020)


Ken Broo of 700 WLW Radio interviews PCS Advisers’ Managing Partner Paul Seegert on the topic of how COVID-19 vaccines should be distributed. (26 November 2020)


Leave a Reply

Your email address will not be published. Required fields are marked *

SPEAK WITH AN ADVISER
Start Here